IL136369A0 - Adamantane derivatives - Google Patents

Adamantane derivatives

Info

Publication number
IL136369A0
IL136369A0 IL13636998A IL13636998A IL136369A0 IL 136369 A0 IL136369 A0 IL 136369A0 IL 13636998 A IL13636998 A IL 13636998A IL 13636998 A IL13636998 A IL 13636998A IL 136369 A0 IL136369 A0 IL 136369A0
Authority
IL
Israel
Prior art keywords
adamantane derivatives
pharmaceutical compositions
derivatives
adamantane
therapy
Prior art date
Application number
IL13636998A
Other languages
English (en)
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of IL136369A0 publication Critical patent/IL136369A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13636998A 1997-12-05 1998-12-01 Adamantane derivatives IL136369A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704544A SE9704544D0 (sv) 1997-12-05 1997-12-05 Novel compounds
PCT/SE1998/002188 WO1999029661A1 (en) 1997-12-05 1998-12-01 Adamantane derivatives

Publications (1)

Publication Number Publication Date
IL136369A0 true IL136369A0 (en) 2001-06-14

Family

ID=20409281

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13636998A IL136369A0 (en) 1997-12-05 1998-12-01 Adamantane derivatives

Country Status (25)

Country Link
US (3) US6201024B1 (xx)
EP (1) EP1036059B1 (xx)
JP (1) JP2001525392A (xx)
KR (1) KR20010032814A (xx)
CN (1) CN1284057A (xx)
AT (1) ATE224360T1 (xx)
AU (1) AU744280B2 (xx)
BR (1) BR9813390A (xx)
CA (1) CA2312420A1 (xx)
DE (1) DE69808130T2 (xx)
DK (1) DK1036059T3 (xx)
EE (1) EE200000378A (xx)
ES (1) ES2184352T3 (xx)
HU (1) HUP0004434A3 (xx)
ID (1) ID28003A (xx)
IL (1) IL136369A0 (xx)
NO (1) NO20002786L (xx)
NZ (1) NZ504447A (xx)
PL (1) PL340906A1 (xx)
PT (1) PT1036059E (xx)
RU (1) RU2214997C2 (xx)
SE (1) SE9704544D0 (xx)
SK (1) SK8432000A3 (xx)
TR (1) TR200001605T2 (xx)
WO (1) WO1999029661A1 (xx)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3742100A (en) * 1999-03-16 2000-10-04 Glaxo Group Limited Nuclear receptor arylating compounds
TR200102911T2 (tr) 1999-04-09 2002-01-21 Astrazeneca Ab Adamantan türevleri.
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
JP2002330787A (ja) * 2000-10-21 2002-11-19 Astrazeneca Ab 化学物質
US7795468B2 (en) * 2001-01-19 2010-09-14 Chevron U.S.A. Inc. Functionalized higher diamondoids
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
SE524951C2 (sv) * 2001-09-02 2004-10-26 Sandvik Ab Användning av en duplex rostfri stållegering
SE524952C2 (sv) * 2001-09-02 2004-10-26 Sandvik Ab Duplex rostfri stållegering
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
AU2003214462A1 (en) 2002-04-03 2003-10-13 Astrazeneca Ab Indole derivatives having anti-angiogenetic activity
US7582309B2 (en) * 2002-11-15 2009-09-01 Etex Corporation Cohesive demineralized bone compositions
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
EP1626962B1 (en) * 2003-05-12 2007-02-28 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
CA2526883A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor .alpha.
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
EP2626354A1 (en) 2004-02-20 2013-08-14 Boehringer Ingelheim International GmbH Viral polymerase inhibitors
MXPA06014022A (es) * 2004-06-29 2007-02-08 Pfizer Prod Inc Prcedimientos para preparar inhibidores de p2x7.
MXPA06015273A (es) * 2004-06-29 2007-03-15 Pfizer Prod Inc Procedimiento para preparar derivados de 5-[4-(2-hidroxi -etil)-3, 5-dioxo-4, 5-dihidro-3h-[1, 2, 4]-triazin -2-il]-benzamida con actividad inhibidora de p2x7 mediante reaccion del derivado no sustituido en posicion 4 de la triazina con un oxirano en
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
US20060063834A1 (en) * 2004-09-09 2006-03-23 Frangioni John V Substituted adamantanes, and methods of making the same
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
EP2527337A1 (en) * 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
EP1891002B1 (en) * 2005-06-06 2012-05-30 Merck Sharp & Dohme Limited Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia
MX2008011919A (es) 2006-03-16 2008-11-28 Renovis Inc Compuestos de bicicloheteroarilo como moduladores de p2x7 y usos de los mismos.
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
ES2569677T3 (es) 2006-03-16 2016-05-12 Second Genome, Inc. Compuestos bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
PL2049478T3 (pl) * 2006-07-06 2012-09-28 Glaxo Group Ltd Podstawione N-fenylometylo 5-okso-prolino-2-amidy jako antagoniści receptora P2X7 oraz sposoby ich zastosowania
JP2010510987A (ja) 2006-11-27 2010-04-08 ハー・ルンドベック・アクチエゼルスカベット ヘテロアリールアミド誘導体
EP2124562B1 (en) 2007-03-09 2016-04-20 Second Genome, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
PE20091225A1 (es) 2007-03-22 2009-09-16 Astrazeneca Ab Derivados de quinolina como antagonistas del receptor p2x7
GB0705882D0 (en) 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
WO2008116845A1 (en) * 2007-03-28 2008-10-02 Glaxo Group Limited Piperidinone carboxamide derivatives as p2x7 modulators
EP2155744A1 (en) 2007-04-10 2010-02-24 Lundbeck, H., A/S Heteroaryl amide analogues as p2x7 antagonists
SI2178865T1 (sl) 2007-07-19 2015-11-30 Lundbeck, H., A/S 5-členski heterociklični amidi in sorodne spojine
EP2215089B1 (en) 2007-11-02 2012-06-27 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b]pyridine-4-yl]-phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
BRPI0910034B1 (pt) 2008-03-25 2022-02-08 Affectis Pharmaceuticals Ag Antagonistas do p2x7r e composições farmacêuticas que os compreendem
RU2386616C2 (ru) 2008-04-23 2010-04-20 Общество С Ограниченной Ответственностью "Бинатех" Производные 5-гидрокси-4-аминометил-1-циклогексил (или циклогептил)-3-алкоксикарбонилиндолов, их фармацевтически приемлемые соли, обладающие противовирусной активностью, и способ их получения
CN102264702B (zh) 2008-12-23 2015-03-25 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮酰胺
CN102264723B (zh) 2008-12-23 2014-12-10 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮酰胺
CA2745866A1 (en) 2008-12-23 2010-07-01 F.Hoffmann-La Roche Ag Dihydropyridone ureas as p2x7 modulators
EP2243772B1 (en) 2009-04-14 2012-01-18 Affectis Pharmaceuticals AG Novel P2X7R antagonists and their use
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase
AU2011252351A1 (en) 2010-05-14 2012-10-11 Affectis Pharmaceuticals Ag Novel methods for the preparation of P2X7R antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
KR101957843B1 (ko) * 2011-10-06 2019-03-14 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2014056620A1 (en) * 2012-10-11 2014-04-17 Grünenthal GmbH Treatment and/or prophylaxis of tspo mediated diseases and/or disorders
CA2890886C (en) * 2012-12-12 2020-10-27 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
WO2014097140A1 (en) * 2012-12-18 2014-06-26 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
KR102529578B1 (ko) 2014-08-29 2023-05-09 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
WO2016032182A1 (ko) * 2014-08-29 2016-03-03 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
WO2020037350A1 (en) * 2018-08-24 2020-02-27 The University Of Sydney Adamantanyl-substituted benzamide compounds and their use as p2x7 receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US3732305A (en) * 1970-03-03 1973-05-08 Us Army S-substituted thiosulfuric acid derivatives and preparation thereof
US3789072A (en) 1970-04-22 1974-01-29 Squibb & Sons Inc Carboxamides
CA2015473C (en) * 1989-04-28 1998-04-14 Iwao Kinoshita Triphenylmethane derivatives
CA2091194A1 (en) * 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
CA2167154A1 (en) * 1993-08-10 1995-02-16 Sarkis Barret Kalindjian Gastrin and cck receptor ligands
GB9409150D0 (en) 1994-05-09 1994-06-29 Black James Foundation Cck and gastrin receptor ligands

Also Published As

Publication number Publication date
JP2001525392A (ja) 2001-12-11
DE69808130D1 (de) 2002-10-24
ID28003A (id) 2001-05-03
US6201024B1 (en) 2001-03-13
RU2214997C2 (ru) 2003-10-27
US6303659B2 (en) 2001-10-16
NO20002786D0 (no) 2000-05-31
EP1036059B1 (en) 2002-09-18
PL340906A1 (en) 2001-03-12
CA2312420A1 (en) 1999-06-17
US20010003121A1 (en) 2001-06-07
TR200001605T2 (tr) 2000-10-23
EP1036059A1 (en) 2000-09-20
AU1791399A (en) 1999-06-28
BR9813390A (pt) 2000-10-03
ATE224360T1 (de) 2002-10-15
SE9704544D0 (sv) 1997-12-05
SK8432000A3 (en) 2000-12-11
CN1284057A (zh) 2001-02-14
EE200000378A (et) 2001-12-17
PT1036059E (pt) 2003-02-28
NO20002786L (no) 2000-07-31
DE69808130T2 (de) 2003-05-28
HUP0004434A2 (hu) 2001-05-28
KR20010032814A (ko) 2001-04-25
US6258838B1 (en) 2001-07-10
NZ504447A (en) 2002-04-26
DK1036059T3 (da) 2002-12-02
ES2184352T3 (es) 2003-04-01
HUP0004434A3 (en) 2002-12-28
AU744280B2 (en) 2002-02-21
WO1999029661A1 (en) 1999-06-17

Similar Documents

Publication Publication Date Title
HK1028594A1 (en) Adamantane derivatives
IL136369A0 (en) Adamantane derivatives
MY125978A (en) Admantane derivatives
SE9704546D0 (sv) Novel compounds
AP9801392A0 (en) Concentrated antibody preparation.
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
IL128601A (en) 7alpha-(epsilon-AMINOALKYL) ESTRATRIENES, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 7alpha-(epsilon-AMINOALKYL) ESTRATRIENES AND THEIR USE FOR PREPARING MEDICAMENTS
HUP9900974A3 (en) Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
HUP9603495A2 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-compounds, pharmaceutical compositions containing the same and process for their preparation
HUP9901086A3 (en) Arylsulfonylaminobenzene derivatives, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions
GR1003350B (el) Νεες ενωσεις
ZA965752B (en) Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents.
HK1040980A1 (zh) 聯苯磺酰基氨基氰、其製備方法及其作為藥物的用途
HUP9901485A2 (en) Heterocyclylcarboxamide derivatives, pharmaceutical compositions containing the same, process for their preparation and their use
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
ZA9610460B (en) New phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions.
ZA989781B (en) Novel bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them.
HUP0003104A3 (en) Amino-spiropiperidin-quinazoline derivatives, their use, process for their preparation and pharmaceutical compositions containing them
ZA9810403B (en) New epothilon derivatives, process for their preparation and their pharmaceutical use.
EP0643060A3 (de) Sulfonylbenzyl-substituierte Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln.
SI0920441T1 (en) 7alpha-(epsilon-aminoalkyl)-estratrienes, process for preparing the same, pharmaceutical preparations containing said 7alpha-(epsilon-aminoalkyl)-estratrienes and their use for preparing medicament
ZA9811804B (en) 11ß-halogen-7Ó-substituted estratrienes, process for the production of pharmaceutical preparations that contain these 11ß-halogen-7Ó-substituted estratrienes as well as their use for the production of pharmaceutical agents.
ZA986139B (en) Sulphonamide compounds, processes for their preparation, pharmaceutical compositions containing the same and their use in therapy.